- Open Access
Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation
Genome Medicine volume 13, Article number: 56 (2021)
Preclinical studies and early clinical trials have shown that targeting cancer neoantigens is a promising approach towards the development of personalized cancer immunotherapies. DNA vaccines can be rapidly and efficiently manufactured and can integrate multiple neoantigens simultaneously. We therefore sought to optimize the design of polyepitope DNA vaccines and test optimized polyepitope neoantigen DNA vaccines in preclinical models and in clinical translation.
We developed and optimized a DNA vaccine platform to target multiple neoantigens. The polyepitope DNA vaccine platform was first optimized using model antigens in vitro and in vivo. We then identified neoantigens in preclinical breast cancer models through genome sequencing and in silico neoantigen prediction pipelines. Optimized polyepitope neoantigen DNA vaccines specific for the murine breast tumor E0771 and 4T1 were designed and their immunogenicity was tested in vivo. We also tested an optimized polyepitope neoantigen DNA vaccine in a patient with metastatic pancreatic neuroendocrine tumor.
Our data support an optimized polyepitope neoantigen DNA vaccine design encoding long (≥20-mer) epitopes with a mutant form of ubiquitin (Ubmut) fused to the N-terminus for antigen processing and presentation. Optimized polyepitope neoantigen DNA vaccines were immunogenic and generated robust neoantigen-specific immune responses in mice. The magnitude of immune responses generated by optimized polyepitope neoantigen DNA vaccines was similar to that of synthetic long peptide vaccines specific for the same neoantigens. When combined with immune checkpoint blockade therapy, optimized polyepitope neoantigen DNA vaccines were capable of inducing antitumor immunity in preclinical models. Immune monitoring data suggest that optimized polyepitope neoantigen DNA vaccines are capable of inducing neoantigen-specific T cell responses in a patient with metastatic pancreatic neuroendocrine tumor.
We have developed and optimized a novel polyepitope neoantigen DNA vaccine platform that can target multiple neoantigens and induce antitumor immune responses in preclinical models and neoantigen-specific responses in clinical translation.
Cancer neoantigens are created by somatic DNA alterations resulting in protein sequence changes capable of triggering adaptive immune responses. Next generation sequencing, together with bioinformatics-based computational algorithms, has revolutionized our ability to identify cancer neoantigens [1, 2]. We and others have demonstrated that cancer neoantigens are important targets during cancer immunoediting and that cancer sequencing combined with epitope prediction algorithms can be used to identify and prioritize neoantigens for integration into personalized cancer vaccines [3,4,5]. Conceptual advantages associated with cancer vaccines targeting cancer neoantigens include the fact that neoantigens are not found in normal tissues, decreasing the risk of autoimmunity and/or central immune tolerance.
Neoantigen vaccines based on the synthetic long peptide (SLP), RNA, and dendritic cell (DC) platforms appear to be capable of inducing neoantigen-specific T cell responses, and potential favorable clinical outcomes [6,7,8,9,10,11]. In order to maximize antitumor immunity and to prevent or curtail tumor immune escape, targeting multiple neoantigens simultaneously is desirable. However, manufacturing neoantigen vaccines based on the SLP, RNA, or DC vaccine platforms under good manufacturing practice (GMP) conditions is both time consuming and resource-intensive. In comparison, one of the strengths of the recombinant DNA vaccine platform is the relative ease of manufacture of plasmid DNA on a scale appropriate for personalized vaccines. As such, the recombinant DNA vaccine platform represents an attractive platform for the clinical development of polyepitope neoantigen cancer vaccines.
Advantages of the DNA vaccine platform include its remarkable safety profile, the relative ease of manufacture, and the molecular flexibility that allows integration of multiple neoantigens using a single polyepitope construct. Recent advances in the DNA vaccine platform, such as gene/vector optimization, molecular/formulation adjuvants, and DNA delivery by electroporation, have significantly improved the efficacy of DNA vaccines, and numerous early phase clinical trials are ongoing in the infectious disease and cancer fields . We report here our efforts to optimize the polyepitope neoantigen DNA vaccine in preclinical models to maximize neoantigen presentation and vaccine immunogenicity. We addressed the following questions: (1) are longer epitopes (≥20-mers) processed equally well as minimal epitopes (e.g., 9-mers); (2) will short flanking sequences (spacers) between epitopes enhance antigen processing and reduce creation of junctional epitopes; and (3) will the addition of a mutant form of ubiquitin enhance neoantigen processing and presentation? Our study demonstrates that polyepitope inserts encoding 20–25-mer neoantigen epitopes (with or without spacers) fused with a mutant form of ubiquitin are efficiently processed and presented. Model DNA vaccines designed with this strategy were able to induce immune responses in vivo, and neoantigen DNA vaccines were able to induce antitumor immune responses in preclinical breast cancer models and neoantigen-specific T cell responses in clinical translation.
Female C57BL/6J (H-2b) and Balb/cJ (H-2d) mice were purchased from the Jackson Laboratory (Bar Harbor, ME). HHD II transgenic mice  were originally obtained from Dr. F. Lemonnier (Institut Pasteur, Paris, France) and were maintained in SPF animal facilities. These mice express the transgene Tg (HLA-A/H2-D/B2M) 1Bpe in a mixed background involving B2Mtm1Unc/tm1Unc and H2-D1tm1Bpe/tm1Bpe. They express chimeric MHC-I heavy chain with HLA-A*0201 (α1-α2) and H-2Db (α3-transmembrane and intracytoplasmic domains), allowing the study of HLA-A2-restricted responses in vivo. All animals were used at 7–10 weeks of age. Protocols were approved by the Animal Studies Committee of Washington University School of Medicine (WUSM) and were in accordance with IACUC guidelines and procedures.
Tumors and cell lines
HeLa cells that stably express HLA-A2 (HeLa-A2), murine and human TAP-deficient RMA-S (H-2b) and T2 cells made to express mouse MHC class I molecules were obtained from Dr. T. Hansen (Washington University School of Medicine). E0771  and 4T1.2  are mouse breast cancer cell lines of C57BL/6 (H-2b) and Balb/c (H-2d) origin, respectively. All cells were cultured in RPMI-1640 complete media (Gibco) supplemented with L-glutamine, 10% fetal bovine serum (Atlanta Biologicals, Flowery Branch, GA), sodium pyruvate, non-essential amino acids, and penicillin-streptomycin (Gibco).
Genome sequencing and neoantigen identification
Genomic DNA and RNA were extracted from E0771 and 4T1.2 tumors grown in vivo using commercially available kits (Qiagen). Tails from C57BL/6 and Balb/c mice were used as normal control. Exome and cDNA-capture sequencing were performed as previously described [3, 5]. The pVACseq pipeline, version 1.0.0-beta [16, 17], was applied to identify genetic alterations and prioritize neoantigens based on the tumor/normal sequencing data. Briefly, each genetic alteration resulting in an amino acid change was evaluated in the context of 10–14 flanking amino acids. All sub-peptides containing the substitution were evaluated using the suite of IEDB-provided HLA class I peptide-binding algorithms (netMHC, NetMHCcons, netMHCpan, PickPocket, SMM, and SMMPMBEC). In order to prioritize neoantigen candidates for the study, results with median predicted binding affinities (IC50) less than 500 nm were filtered based on sample purity (both tumor VAF and RNA VAF > 30%), gene expression level (FPKM > 1), and ranked according to the fold change (MT/WT) of IC50 scores. Neoantigens with MT/WT fold change greater than 2 were incorporated in the polyepitope neoantigen DNA vaccines.
Polyepitope DNA and SLP vaccines
Codon-optimized DNA fragment encoding polyepitope neoantigens were synthesized by Blue Heron Biotech (Bothell, WA) or GenScript (Piscataway, NJ) and subsequently cloned into the mammalian expression plasmid pcDNA 3.1(+) (Invitrogen, Carlsbad, CA) or the pMSV.IRES.GFP (pMIG) retroviral expression vector. The sequences of the polyepitope constructs can be found in Additional file 1. Where indicated, DNA sequence for Ubmut, a mutated (G76V) ubiquitin , was fused to the N-terminus of the polyepitope construct by standard molecular subcloning. Plasmid DNA were amplified in Escherichia coli DH5α (Invitrogen) and purified using NucleoBond Maxi Plasmid DNA Purification kits (Macherey-Nagel, Bethlehem, PA). DNA vaccination was performed using a Helios gene gun (Bio-Rad, Hercules, CA) as previously described . Typically, 4 μg of DNA was delivered to non-overlapping shaved and depilated mice abdominal areas at 3-day intervals (days 0, 3, and 6) for a total of three doses . The discharge helium pressure was set to 400 p.s.i. Immune responses were measured 5 days after the last gene gun vaccination (day 11).
SLPs containing the identified neoantigens were custom-made by GenScript and Peptide 2.0 (Chantilly, VA). Lyophilized peptides were first dissolved in H2O or DMSO and stored at − 20 °C. One hundred micrograms of each peptide was diluted in PBS and mixed with 50 μg of poly(I:C) (InvivoGen) before subcutaneous injection on day 0 and day 7. Immune responses were measured by ELISpot assay on day 12.
Immunoprecipitations and immunoblots
HeLa-A2 cells were transduced with a retroviral vector pMIG  encoding polyepitope antigen. GFP+ cells were FACS-sorted and cultured for 24 h with or without 50 μM MG132 (Boston Biochem, Cambridge, MA). Expression of GFP protein was also confirmed by western blot of total cell lysate with anti-GFP antibody (Santa Cruz, Dallas, TX). To detect the production and degradation of polyepitopes, immunoprecipitation and immunoblot were performed as previously described . Briefly, cells were lysed in PBS with 1% Nonidet P-40. Post-nuclear lysates were then incubated with anti-HA-Sepharose (Covance). After washes, precipitated proteins were eluted by boiling in LDS sample buffer (Invitrogen) and separated by SDS-PAGE. Proteins were detected with anti-HA (clone 16B12, Santa Cruz) and visualized by chemiluminescence using the ECL system (ThermoFisher).
To measure cell surface expression of neoantigens, a TCR mimic Ab (TCRm) specific for SVG9/HLA-A2  was used to stain HeLa-A2 cells transduced with polyepitope DNA. As a positive control, parental HeLa-A2 cells were incubated with 10 μM SVG9 peptide for the last hours before cell wash. PE-conjugated goat anti-mouse Ig Ab (BD Biosciences, San Jose, CA) was used as secondary Ab. Data from viable cells, gated by forward and side scatter, were acquired on a FACSCalibur (BD Biosciences) and analyzed using FlowJo v10 software (TreeStar, Ashland, OR).
In vitro CTL assays were performed as previously described . Briefly, target cells (transduced HeLa-A2) were labeled with 0.2 mCi of [51Cr] (PerkinElmer, Wellesley, MA) and incubated with SVG9-specific T cells generated from WNV-KUN-immunized HHDII spleen cells. Parental HeLa-A2 cells with or without SVG9 peptide were used as controls. Maximum lysis was achieved by adding 5% Triton-X 100 (Sigma-Aldrich) to the wells. Spontaneous lysis was determined with cultured target cells without CTLs. Supernatants were collected and read by an Isomedic γ-counter (ICN Biomedicals, Huntsville, AL). The specific lysis was calculated by the formula: 100 × [(experimental 51Cr release − control 51Cr release)/(maximum 51Cr release − spontaneous 51Cr release)].
Tumor challenge and TIL analysis
E0771 and 4T1.2 tumor cells were dislodged with Trypsin/EDTA (ThermoFisher) and washed twice with Ca2+/Mg2+-free PBS. 106 cells were injected subcutaneously into the flanks of female mice. Tumor sizes were measured using an electronic caliper. For checkpoint blockade, 200 μg of anti-PD-L1 (clone 10F.9G2) or isotype control (clone LTF-2) antibody (both from Bio X Cell, West Lebanon, NH) was administered i.p. at the indicated time points.
To study the neoantigen-specific T cells present in the tumor after DNA vaccination, tumors were harvested and digested with Tumor Dissociation Kit (Miltenyi Biotec) following the manufacturer’s instruction. Single cell suspensions were prepared by passing through 70-μm cell strainers after cell debris was removed and red blood cells were lysed. Tumor-infiltrating leukocytes were stained with dextramer and analyzed by flow cytometry.
PE-conjugated SVG9/HLA-A*0201 tetramer was obtained from the National Institute of Allergy and Infectious Diseases tetramer facility (Emory University, Atlanta, GA). APC-conjugated Lrrc27/H-2Db dextramer was manufactured by Immudex (Copenhagen, Denmark). Cells were stained with tetramer or dextramer for 40 min at 37 °C. Fluorophore-labeled antibodies specific for surface markers (CD45, CD3e, and CD8α) were subsequently added and the cells were incubated for an additional 20 min at 4 °C. Cells were acquired on a FACSCalibur and data were analyzed with FlowJo v10 software.
Patient GTB16 was a 25-year-old male with Lynch Syndrome-associated metastatic pancreatic neuroendocrine tumor that was refractory to standard of care treatment. He was initially diagnosed and treated at Barnes-Jewish Hospital, St. Louis, MO. He received palliative carboplatin/etoposide and concurrent lanreotide with a partial response. Because his tumor demonstrated microsatellite instability, he was also treated with pembrolizumab as maintenance therapy on a compassionate use protocol with a partial response. Repeat surveillance MRI demonstrated mixed response with evidence of ongoing progression. Due to the lack of any effective treatment options available, he was treated with a neoantigen DNA vaccine (pGTB16) on a compassionate use basis. The protocol was approved by the Washington University School of Medicine Institutional Review Board, Institutional Biosafety Committee, and the Food and Drug Administration. Written informed consent was signed by the patient for the treatment and associated research studies. A total of three vaccinations with at least 21 days in between injections were administered. pGTB16 vaccine was delivered intramuscularly using an integrated electroporation device (TDS-IM system, Ichor Medical Systems). Blood was drawn pre- and post-vaccination and peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Paque PLUS (GE Healthcare) density centrifugation and cryopreserved. PBMCs were used in IFN-γ ELISpot assay to evaluate the generation of a neoantigen-specific immune response.
IFN-γ ELISpotPLUS Kits (Mabtech, Cincinnati, OH) were used as instructed by the manufacturer to measure the in vivo neoantigen-specific immune response. For preclinical studies, mouse spleen or lymph node cells were typically seeded at 2–4 × 105 per well in triplicates. Neoantigen (MT) and wildtype (WT) counterparts were synthesized by Peptide 2.0 or GenScript and were used at the indicated final concentration. For clinical studies, cryopreserved PBMCs were thawed and cultured for 12 days in the presence of human IL-2 (50 U/mL) and 25 μM each of the pooled overlapping peptides (each pool contained two mutated genes). After an overnight rest in culture medium without peptides and IL-2, 105 of the in vitro-stimulated cells were co-cultured in the ELISpot plate for 20 h with 104 of autologous PBMCs that were pulsed with 100 μM individual long peptide and irradiated (3000 Rad). The ELISpot plates were scanned and analyzed on an ImmunoSpot Reader (CTL, Shanker Heights, OH).
Data were analyzed using GraphPad Prism 8 software (GraphPad, La Jolla, CA) and presented mainly as mean ± SEM. The Mann-Whitney test or one-way ANOVA test were used to compare between vaccination groups. Paired t-test was performed in some cases when different conditions were compared using the same specimens. A P value equal or less than 0.05 is considered statistically significant. Figures were prepared using Adobe Illustrator CS6 (Adobe, San Jose, CA).
Optimizing the design of polyepitope neoantigen DNA vaccines for enhanced presentation and recognition
We first established a model system to optimize the polyepitope DNA vaccine platform by using eight well-characterized HLA-A2-restricted epitopes. This model system allowed us to address important questions about polyepitope design such as size of the neoantigen epitope, inclusion of spacers, and addition of a ubiquitin tag to enhance antigen processing. The HLA-A2-restricted epitopes included viral (EBV, HCMV, influenza, and West Nile Virus) and tumor-associated antigens (melanoma gp100) (Additional file 2, Table S1). With the exception of the CMV (pp65) and influenza (M1) epitopes, the order of the other six epitopes was consistent between the model polyepitope constructs (Fig. 1a, left). The spacer inserted between epitopes consisted of three amino acids (AAY) . To study whether antigen processing efficacy is different for short vs. long epitopes encoded in polyepitope DNA vaccines, we created polyepitope DNA constructs that encode either minimal epitopes (9–10 AA) or longer epitopes (20 AA) with native residues flanking the minimal epitopes. We designated the constructs as P9/P20 (starting with pp65) and M9/M20 (starting with M1). To facilitate in vitro assays, the polyepitope constructs integrated an HA tag at the C-terminus. Co-expression of GFP was made possible through an IRES element and served as control for transduction as measured in immunoblot (IB) analysis or flow cytometry (Fig. 1a, right).
To study the expression and processing of the polyepitope constructs, HeLa-A2 cells were transduced with different constructs. Cell lysates were immunoprecipitated (IP) followed by IB to detect HA-tagged polyepitopes. We found that GFP proteins were equally expressed in the transduced cells, as determined by IB. However, the P9 and P9-spacer constructs were undetectable while M9 and M9-spacer constructs were readily detected (Additional file 3, Fig. S1a, left), suggesting that polyepitopes starting with an unstable amino acid (such as N in pp65) degraded more rapidly than constructs starting with a stable residue (such as G in M1). This observation is consistent with the N-end rule of protein degradation . The addition of spacers in both P9 and M9 constructs resulted in increased surface presentation of SVG9 as determined by flow cytometric analysis using a TCR-mimic antibody specific for SVG9/HLA-A2 . But in the case of construct P20, the addition of spacers did not increase the presentation of SVG9 (Additional file 3, Fig. S1a, middle and right). These data suggest that additional amino acids in the spacers flanking the 9-mer epitopes might help with processing of the intact minimal epitope, but that spacers may not be required if native flanking sequences are present. We therefore decided to focus on the DNA construct P20, which encodes long epitopes.
Because MHC I binding peptides are initially processed in the cytosol by the ubiquitin/proteasome pathway , we hypothesized that integrating a mutant form of ubiquitin (Ub G76V or Ubmut), which is resistant to ubiquitin hydrolysis, to the N-terminus of the polyepitope constructs could accelerate ubiquitination-mediated degradation of the polyepitopes and antigen processing. Indeed, integration of Ubmut before the polyepitope construct resulted in faster protein degradation, compared with the same construct without the addition of Ubmut, as determined by IB analysis (Fig. 1b). The integration of Ubmut does not impact the transduction efficacy and protein expression, as the GFP levels were similar comparing constructs with or without the Ubmut tag. Notably, this increased polyepitope degradation appeared to be associated with a higher surface presentation of HLA-A2/SVG9 complexes (Fig. 1c, left). The degradation of polyepitope proteins was proteasome-dependent, as addition of the proteasomal inhibitor MG132 protected the proteins from rapid degradation (Additional file 3, Fig. S1b). Consistent with the flow cytometric analysis, in a 51Cr-releasing cytotoxicity assay using an A2/G209-specific T cell line, HeLa-A2 cells transduced with Ubmut-P20 were lysed more efficiently compared to cells transduced with P20 (Fig. 1c, middle; Additional file 3, Fig. S1c). Additionally, when the DNA constructs were used to vaccinate HHD II mice, the Ubmut-P20 vaccine generated more robust CD8 T cell responses in vivo compared to the P20 vaccine, as determined by an IFN-γ ELISpot assay (Fig. 1c, right; Additional file 3, Fig. S1d) and SVG9/HLA-A2 tetramer staining (Fig. 1d).
Taken together, these results suggested that a polyepitope DNA construct encoding long epitopes (≥20 mers), in tandem with an Ubmut fused to the N-terminus, is optimal for processing and presentation of epitopes among the constructs tested. This design was therefore used for subsequent studies. Of note, although the optimized vaccine is superior for the majority of the encoded antigens, it is not superior for all antigens compared to the control vaccine (Additional file 3, Fig. S1c).
Optimized polyepitope neoantigen DNA vaccines elicit immune responses in preclinical mouse breast cancer models
We carried out proof-of-concept studies using E0771 and 4T1.2, two syngeneic murine mammary tumors. E0771 and 4T1.2 recapitulate many of the biologic features of human breast cancer, including the dynamic tumor and immune system interactions restraining endogenous immune responses and serve as models of estrogen receptor-positive (ER+) and triple-negative breast cancer (TNBC), respectively [27, 28]. We sequenced both 4T1.2 and E0771 and successfully identified candidate neoantigens with strong predicted binding affinity to the corresponding MHC class I alleles using pVACseq, a computational pipeline [16, 17] (Additional file 2, Table S2 and S3). Polyepitope Ubmut-E0771 and Ubmut-4T1.2 neoantigen DNA vaccines were created and used to vaccinate C57BL/6 or Balb/c mice, respectively. Neoantigen-specific T cell responses were detected by IFN-γ ELISpot assay for three neoantigens (Lrrc27 G330A, Plekho1 P251S, and Pttg1 V53L) encoded in the Ubmut-E0771 polyepitope DNA vaccine (Fig. 2a). Of note, short peptides corresponding to the minimal MHC class I epitopes were used in these assays, suggesting a CD8 T cell response. Neoantigen-specific T cell responses were also detected by IFN-γ ELISpot assay for four neoantigens (Gyk K505R, Gpld1 R829W, Pram1 Q572L and Aars2 A697P) encoded in the Ubmut-4T1.2 polyepitope DNA vaccine (Fig. 2b). All four 4T1.2 neoantigens are known to contain CD4 epitopes as spleen CD4+ T cells isolated from mice vaccinated with peptides responded to peptide restimulation ex vivo (Additional file 3, Fig. S2). These results confirmed the ability of neoantigen DNA vaccines incorporating Ubmut-polyepitope inserts to generate robust immune responses in clinically relevant preclinical models.
We created additional constructs that did not integrate the mutant ubiquitin tag in the E0771 model system. E0771 polyepitope DNA vaccines with or without the Ubmut tag were used to vaccinate C57BL/6 mice. Results from IFN-γ ELISpot assays demonstrated no statistically significant difference in the ability to induce neoantigen-specific immune responses (data not shown).
Optimized polyepitope neoantigen DNA vaccines in combination with checkpoint blockade inhibit tumor growth in preclinical models
We next investigated whether antitumor immunity can be generated by polyepitope neoantigen DNA vaccines. In an initial study, polyepitope Ubmut-E0771 DNA vaccine alone, in either prophylactic or therapeutic settings, had only a marginal impact on subcutaneously transplanted E0771 tumor growth (data not shown). However, when combined with anti-PD-L1 ICB therapy, the polyepitope Ubmut-E0771 neoantigen DNA vaccine was able to enhance the antitumor response and suppress E0771 tumor growth for the duration of the experiment (Fig. 3a, b). At day 14, robust neoantigen-specific T cell responses were detected in tumors (Fig. 3c) and tumor-draining lymph nodes (Fig. 3d) following treatment with neoantigen DNA vaccines alone, or neoantigen DNA vaccines plus anti-PD-L1 antibody. At day 26, neoantigen-specific T cell responses persisted only in mice treated with neoantigen DNA vaccines plus anti-PD-L1 antibody (Fig. 3e). In mice that received neoantigen DNA vaccines but not anti-PD-L1 antibody, neoantigen-specific T cell responses returned to baseline. These data suggest that in the setting of a tumor-bearing mouse, addition of anti-PD-L1 is required for persistent antitumor immunity following neoantigen DNA vaccine treatment.
Unlike E0771, which is responsive to anti-PD-L1 treatment, 4T1.2 is resistant to anti-PD-L1 monotherapy (Additional file 3, Fig. S3a). In a pilot study, we found that Ubmut-4T1.2 polyepitope DNA vaccine alone was able to partially inhibit tumor growth in vivo (Additional file 3, Fig. S3b). Further investigation is needed to understand the changes in immune system and whether ICB treatment will enhance the antitumor immunity induced by Ubmut-4T1.2 polyepitope DNA vaccine.
Optimized polyepitope DNA vaccines induce similar magnitude of immune responses as synthetic long peptides
We compared the efficacy of polyepitope neoantigen DNA vaccines with that of neoantigen SLP vaccines. Vaccine schedules were optimized for each platform by testing different doses and vaccination time points (DNA vaccine), or different doses, vaccination time points and molecular adjuvants (SLP vaccine) (data not shown). IFN-γ ELISpot assays performed on the same day indicated that the Ubmut-E0771 polyepitope neoantigen DNA vaccine and the neoantigen SLP vaccine generated similar levels of T cell responses specific to the three neoantigens (Fig. 4a). Likewise, polyepitope Ubmut-4T1.2 DNA vaccine and SLP vaccine generated similar levels of T cell responses specific to the four neoantigens (data not shown).
Specificity of the immune response was further investigated by means of cross-reactivity against corresponding germline (wildtype) Lrrc27, Plekho1, and Pttg1 epitopes over a range of concentrations. At physiologic concentrations, no reactivity was detected against all three WT epitopes (Fig. 4b and data not shown). Of note, one of the wild-type peptides (Lrrc27) was predicted to be a strong binder, with a predicted binding affinity of 408.48 nM to H-2Db [netMHC 4.0 , http://www.cbs.dtu.dk/services/NetMHC]. Additional analysis revealed that both MT and WT Lrrc27 peptides bind equally well to H-2Db (Additional file 3, Fig. S4A). At relatively high concentration, some cross-reactivity was observed against WT Lrrc27 peptide following vaccination with either polyepitope DNA or SLP vaccines (Fig. 4b and Additional file 3,Fig. S4b). These data suggest that T cells induced by polyepitope Ubmut-E0771 DNA vaccines preferably recognize MT neoantigens over WT counterparts when the density of peptide-MHC complexes is low. Such specificity to neoepitopes is critical as tumor cells typically only display relatively few neoantigen-MHC complexes.
An optimized polyepitope neoantigen DNA vaccine induced neoantigen-specific T cell responses in a patient with metastatic neuroendocrine tumor
Cancer patient GTB16 was treated with an optimized polyepitope neoantigen DNA vaccine. The pGTB16 vaccine was constructed as described for the preclinical studies and was manufactured in the GMP facility at WUSM. The DNA sequence of the pGTB16 construct and a list of targeted neoantigens can be found in Additional file 1 and Additional file 2, Table S4. IFNγ ELISpot assay performed after in vitro stimulation indicated that the polyepitope neoantigen DNA vaccine was able to induce T cell responses against select neoantigens. For this patient, 13 neoantigens were targeted by the DNA vaccine. Specific responses above background were demonstrated against three neoantigens (TBC1D22A:p.R437S, TRPC4AP:p.T63M, and ZNF611:p.D404G, Fig. 5).
Recombinant DNA vaccines can generate potent immune responses [30,31,32,33] and have progressed into clinical trials targeting infectious disease agents and cancer . DNA vaccines are stable, relatively easy to design and manufacture, and less expensive than synthetic long peptide, viral or cell-based vaccine platforms. More importantly, the molecular flexibility of the DNA vaccine platform allows genetic modification of encoded antigens, and/or incorporation of immune modulators to improve immunogenicity. In this study, we constructed polyepitope DNA vaccines encoding multiple cancer neoantigens and evaluated multiple parameters of the vaccine design including the length of neoepitopes, inclusion of spacers, and/or inclusion of a mutant ubiquitin construct to enhance antigen presentation.
The polyepitope approach has been studied previously and proved to be effective in priming T cell responses against viral and conventional tumor antigens [24, 35,36,37]. Polyepitope proteins require additional intracellular processing in order to be loaded onto MHC molecules. Studies of peptide vaccination in incomplete Freund’s adjuvant (IFA) showed that longer peptides (25-mers) in IFA can generate sustained CD8 T cell reactivity while shorter peptides (8–10-mers) corresponding to minimal epitopes induced only short-lived CD8 T cell responses . This may result from altered antigen processing with minimal epitopes, or the inclusion of both CD4 and CD8 epitopes in the longer epitopes. Since the goal of neoantigen cancer vaccines is to generate a robust and long-lasting cancer-specific immune response, we chose to evaluate both short and long neoepitopes in the DNA vaccines, with the understanding that maximizing presentation of long neoepitopes would be preferred. There is now evidence to suggest that long neoantigens may contain neoantigen-specific CD4 helper T cell epitopes with the potential to induce a more balanced CD8/CD4 response. Recent studies demonstrate that CD4 T cell responses were induced by neoantigen vaccines even though neoantigen prioritization was based primarily on the binding affinity to MHC class I [7, 9, 39]. Our data confirm that long neoantigens are equally well processed and can induce robust neoantigen-specific CD8 and CD4 T cell responses in vivo.
Amino acids flanking minimal epitopes play an important role in TAP-binding and proteasomal cleavage. Researchers have used artificial linkers [24, 37] and furin cleavage sites  to facilitate proteolytic cleavage and antigen presentation. Previous studies indicated a preference of natural flanking sequences in TAP-dependent antigen presentation . Some peptides are efficiently presented by MHC I molecules but are poorly transported by TAP as minimal epitopes. Research suggested that they can be more efficiently transported by TAP as larger fragments with natural flanking amino acids, which can be further trimmed in the endoplasmic reticulum (ER) and bind to MHC class I molecules . In the current study, we found that epitopes flanked by natural sequences can be processed and presented effectively and adding a linker does not further enhance antigen presentation. In order to minimize the risk of junctional neoepitopes, we have developed a robust tool (pVACvector) to assess for the presence of junctional epitopes. pVACvector starts with the list of prioritized neoantigens and uses the pVACseq software to predict the binding score for each possible junctional peptide. This information is used to order the neoantigen sequences in a way that minimizes junctional epitopes . Current version of the pVACtools suite, which contains pVACseq and pVACvector, is available at Github .
To enhance antigen presentation, we explored integration of a mutant ubiquitin tag as part of the polyepitope DNA vaccine to facilitate protein degradation and maximize antigen presentation. Early studies in the yeast Saccharomyces cerevisiae demonstrated that a monoubiquitin conjugate can function as protein degradation signal . Fusion of a ubiquitin molecule to a polyepitope DNA vaccine was able to enhance CTL priming and improve antitumor immune responses in an HPV-induced preclinical model . However, natural ubiquitin fusions are unstable and prone to deubiquitination under physiological conditions. The modification at the C-terminal portion of ubiquitin, replacing the glycine with a valine (G76V), metabolically stabilizes the fusion as revealed by pulse-chase analysis [42, 43]. This “uncleavable” Ubmut has been a useful tool in studying cell cycle and apoptosis , as wells as autophagy . We have demonstrated in this study that the Ubmut tag does indeed improve antigen processing and presentation, which in turn results in an enhanced immune response in vitro (Fig. 1).
We created polyepitope DNA vaccines encoding neoantigens identified in mouse breast cancer models and tested these vaccines in vivo. Polyepitope DNA vaccines were able to induce robust T cell responses to some but not all neoantigens. This underscores the need for further improvement of neoantigen prediction algorithms. Our finding that a polyepitope neoantigen DNA vaccine can induce robust T cell responses and antitumor immunity is consistent with a recent report . Although our findings confirm and extend the results of Duperret et al., the polyepitope DNA vaccine designs evaluated here are distinct. Duperret et al. constructed polyepitope DNA vaccines encoding 33-mer neoantigens separated by furin cleavage sites. We demonstrate that furin cleavage sites are not required for robust neoantigen presentation, and we have leveraged a publically available software tool, pVACvector, to optimize the order of neoantigens so that the risk of introducing junctional epitopes is minimized. In addition, we integrated the Ubmut tag to the constructs, which clearly improves antigen processing and presentation, and potentially the downstream immune responses. Of note, the optimized polyepitope vaccine is not superior for every neoantigen/model tested. For instance, a side-by-side comparison of polyepitope DNA vaccines with or without the Ubmut tag targeting the same neoantigens identified in E0771 showed no statistically significant difference in magnitude of neoantigen-specific responses. We hypothesize that some neoantigens are efficiently processed and may not require targeting to the ubiquitin pathway for presentation, while others are less efficiently processed and benefit from targeting to the ubiquitin pathway.
In spite of the ability to generate neoantigen-specific T cell responses, the neoantigen DNA vaccines alone were not able to protect animals from transplanted E0771 and 4T1.2 tumors. We present our observation that combinatorial immunotherapy of neoantigen DNA vaccine plus anti-PD-L1 checkpoint blockade is capable of suppressing E0771 tumor growth. One limitation in our study is that we did not study in detail the mechanism(s) of the antitumor immunity rendered by the optimized polyepitope neoantigen DNA vaccine +/− ICB immunotherapy. Research into the cellular and molecular changes occurring in the tumor microenvironment following combination therapy with ICB and neoantigen DNA vaccine is currently underway in novel genetic models. Preliminary data suggest that tumor growth inhibition by combination immunotherapy is associated with sustained neoantigen-specific T cell responses and CD8 T cell infiltration into the tumor (Fig. 3c–e). The recent clinical success of ICB in treating various types of cancer [reviewed in [45,46,47]] has pushed it towards the forefront of cancer therapy. We have initiated a randomized phase 1 clinical trial that tests the efficacy of a polyepitope neoantigen DNA vaccine +/− anti-PD-L1 in patients with triple negative breast cancer (NCT03199040). This trial represents unique bench-to-bedside-to-bench opportunities to enhance the efficacy of neoantigen vaccines and checkpoint blockade therapy.
Finally, we have treated a patient with metastatic neuroendocrine tumor with a polyepitope neoantigen DNA vaccine. This is the first report of the use of a neoantigen DNA vaccine in humans. The tumor of this patient was refractory to standard of care treatment and showed evidence of ongoing progression at the time when the vaccination started on a compassionate use basis. Our data demonstrate that polyepitope neoantigen DNA vaccines are capable of inducing neoantigen-specific T cell responses. The successful clinical translation of polyepitope neoantigen DNA vaccines will likely depend on refinement of neoantigen prediction algorithms, combination therapies targeting the tumor microenvironment, and an improved ability to assess the antitumor potential of neoantigen-specific T cells. In this study, we observed neoantigen-specific T cell responses to 3/13 neoantigens included in the vaccine, highlighting the need to further refine current neoantigen prediction algorithms. In addition, neoantigen-specific T cells may not be effective in mediating antitumor immunity if these T cells are suppressed in the tumor microenvironment. For future studies, we are planning to use innovative technologies such as CyTOF, IMC, and CODEX, to investigate the phenotype and function of neoantigen-specific T cells in the tumor, and the impact of combination therapy on the tumor microenvironment. These technologies will allow a better understanding of the antitumor potential of neoantigen-specific T cells.
We have optimized a polyepitope DNA vaccine design to encode multiple neoantigens. Tumor/normal whole exome sequencing and RNA sequencing were used to identify and prioritize neoantigens in the E0771 and 4T1.2 preclinical breast cancer models, as well as a patient with metastatic pancreatic neuroendocrine tumor. E0771 and 4T1.2-specific polyepitope neoantigen DNA vaccines were able to induce robust immune responses and inhibit tumor growth when combined with anti-PD-L1 checkpoint blockade immunotherapy. Similarly, neoantigen-specific immune responses were detected after vaccination in a patient with metastatic neuroendocrine tumor. The results provide strong evidence to support clinical translation of a polyepitope neoantigen DNA vaccine strategy. We are currently evaluating the polyepitope neoantigen DNA vaccine platform in phase 1 clinical trials in breast and pancreas cancer (NCT03199040 and NCT03122106).
Availability of data and materials
Processed data generated during this study are included in this published article and its additional files. Mouse sequence data are available at the Sequence Read Archive under BioProject PRJNA685845 https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA685845 . Human sequence data/analyses have been deposited in and are available from the dbGaP database under dbGaP study accession phs002342.v1.p1 http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002342.v1.p1 .
Cytotoxic T lymphocyte
Enzyme-linked immune absorbent spot
Human leukocyte antigen
Immune checkpoint blockade
Incomplete Freund’s adjuvant
Major histocompatibility complex
Peripheral blood mononuclear cell
Synthetic long peptide
Transporter associated with antigen processing
T cell receptor
Triple-negative breast cancer
Li L, Goedegebuure P, Mardis ER, Ellis MJ, Zhang X, Herndon JM, et al. Cancer genome sequencing and its implications for personalized cancer vaccines. Cancers (Basel). 2011;3(4):4191–211. https://doi.org/10.3390/cancers3044191.
Li L, Goedegebuure SP, Gillanders WE. Preclinical and clinical development of neoantigen vaccines. Ann Oncol. 2017;28(suppl_12):xii11–xii7.
Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SSK, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJM, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515(7528):577–81. https://doi.org/10.1038/nature13988.
Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, Hundal J, Wendl MC, Demeter R, Wylie T, Allison JP, Smyth MJ, Old LJ, Mardis ER, Schreiber RD. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012;482(7385):400–4. https://doi.org/10.1038/nature10755.
Zhang X, Kim S, Hundal J, Herndon JM, Li S, Petti AA, Soysal SD, Li L, McLellan MD, Hoog J, Primeau T, Myers N, Vickery TL, Sturmoski M, Hagemann IS, Miller CA, Ellis MJ, Mardis ER, Hansen T, Fleming TP, Goedegebuure SP, Gillanders WE. Breast cancer neoantigens can induce CD8+ T-cell responses and antitumor immunity. Cancer Immunol Res. 2017;5(7):516–23. https://doi.org/10.1158/2326-6066.CIR-16-0264.
Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, Ly A, Lie WR, Hildebrand WH, Mardis ER, Linette GP. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015;348(6236):803–8. https://doi.org/10.1126/science.aaa3828.
Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217–21. https://doi.org/10.1038/nature22991.
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira AL, Ibrahim F, Bruggeman C, Gasmi B, Zappasodi R, Maeda Y, Sander C, Garon EB, Merghoub T, Wolchok JD, Schumacher TN, Chan TA. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–8. https://doi.org/10.1126/science.aaa1348.
Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Lower M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222–6. https://doi.org/10.1038/nature23003.
Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanovic S, Gouttefangeas C, et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2019;565(7738):240–5. https://doi.org/10.1038/s41586-018-0810-y.
Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, Oliveira G, Giobbie-Hurder A, Felt K, Gjini E, Shukla SA, Hu Z, Li L, le PM, Allesøe RL, Richman AR, Kowalczyk MS, Abdelrahman S, Geduldig JE, Charbonneau S, Pelton K, Iorgulescu JB, Elagina L, Zhang W, Olive O, McCluskey C, Olsen LR, Stevens J, Lane WJ, Salazar AM, Daley H, Wen PY, Chiocca EA, Harden M, Lennon NJ, Gabriel S, Getz G, Lander ES, Regev A, Ritz J, Neuberg D, Rodig SJ, Ligon KL, Suvà ML, Wucherpfennig KW, Hacohen N, Fritsch EF, Livak KJ, Ott PA, Wu CJ, Reardon DA. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019;565(7738):234–9. https://doi.org/10.1038/s41586-018-0792-9.
Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet. 2008;9(10):776–88. https://doi.org/10.1038/nrg2432.
Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med. 1997;185(12):2043–51. https://doi.org/10.1084/jem.185.12.2043.
Snell GD, Cloudman AM, Woodworth E. Tumor immunity in mice, induced with lyophilized tissue, as influenced by tumor strain, host strain, source of tissue, and dosage. Cancer Res. 1948;8(9):429–37.
Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, Lowen D, Javni J, Miller FR, Slavin J, Anderson RL. A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis. 1999;17(2):163–70. https://doi.org/10.1023/A:1006689719505.
Hundal J, Carreno BM, Petti AA, Linette GP, Griffith OL, Mardis ER, Griffith M. pVAC-Seq: a genome-guided in silico approach to identifying tumor neoantigens. Genome Med. 2016;8(1):11. https://doi.org/10.1186/s13073-016-0264-5.
Hundal J, Kiwala S, McMichael J, Miller CA, Xia H, Wollam AT, Liu CJ, Zhao S, Feng YY, Graubert AP, Wollam AZ, Neichin J, Neveau M, Walker J, Gillanders WE, Mardis ER, Griffith OL, Griffith M. pVACtools: a computational toolkit to identify and visualize cancer neoantigens. Cancer Immunol Res. 2020;8(3):409–20. https://doi.org/10.1158/2326-6066.CIR-19-0401.
Dantuma NP, Lindsten K, Glas R, Jellne M, Masucci MG. Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nat Biotechnol. 2000;18(5):538–43. https://doi.org/10.1038/75406.
Li L, Herndon JM, Truscott SM, Hansen TH, Fleming TP, Goedegebuure P, Gillanders WE. Engineering superior DNA vaccines: MHC class I single chain trimers bypass antigen processing and enhance the immune response to low affinity antigens. Vaccine. 2010;28(8):1911–8. https://doi.org/10.1016/j.vaccine.2009.10.096.
Bins AD, Jorritsma A, Wolkers MC, Hung CF, Wu TC, Schumacher TN, et al. A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med. 2005;11(8):899–904. https://doi.org/10.1038/nm1264.
Lybarger L, Wang X, Harris MR, Virgin HW, Hansen TH. Virus subversion of the MHC class I peptide-loading complex. Immunity. 2003;18(1):121–30. https://doi.org/10.1016/S1074-7613(02)00509-5.
Wang X, Yu YY, Myers N, Hansen TH. Decoupling the role of ubiquitination for the dislocation versus degradation of major histocompatibility complex (MHC) class I proteins during endoplasmic reticulum-associated degradation (ERAD). J Biol Chem. 2013;288(32):23295–306. https://doi.org/10.1074/jbc.M113.482018.
Kim S, Li L, McMurtrey CP, Hildebrand WH, Weidanz JA, Gillanders WE, et al. Single-chain HLA-A2 MHC trimers that incorporate an immundominant peptide elicit protective T cell immunity against lethal West Nile virus infection. J Immunol. 2010;184(8):4423–30. https://doi.org/10.4049/jimmunol.0903955.
Velders MP, Weijzen S, Eiben GL, Elmishad AG, Kloetzel PM, Higgins T, Ciccarelli RB, Evans M, Man S, Smith L, Kast WM. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J Immunol. 2001;166(9):5366–73. https://doi.org/10.4049/jimmunol.166.9.5366.
Varshavsky A. The N-end rule pathway of protein degradation. Genes Cells. 1997;2(1):13–28. https://doi.org/10.1046/j.1365-2443.1997.1020301.x.
Rock KL, Goldberg AL. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol. 1999;17(1):739–79. https://doi.org/10.1146/annurev.immunol.17.1.739.
Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 1992;52(6):1399–405.
Ewens A, Mihich E, Ehrke MJ. Distant metastasis from subcutaneously grown E0771 medullary breast adenocarcinoma. Anticancer Res. 2005;25(6B):3905–15.
Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, Nielsen M. NetMHCpan-4.0: improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J Immunol. 2017;199(9):3360–8. https://doi.org/10.4049/jimmunol.1700893.
Davis HL, Michel ML, Whalen RG. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum Mol Genet. 1993;2(11):1847–51. https://doi.org/10.1093/hmg/2.11.1847.
Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A. 1993;90(24):11478–82. https://doi.org/10.1073/pnas.90.24.11478.
Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature. 1992;356(6365):152–4. https://doi.org/10.1038/356152a0.
Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski S, Deck R, DeWitt C, Friedman A, et Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 1993;259(5102):1745–9, doi: https://doi.org/10.1126/science.8456302.
Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, Weiner DB. Clinical applications of DNA vaccines: current progress. Clin Infect Dis. 2011;53(3):296–302. https://doi.org/10.1093/cid/cir334.
Alexander J, Oseroff C, Dahlberg C, Qin M, Ishioka G, Beebe M, Fikes J, Newman M, Chesnut RW, Morton PA, Fok K, Appella E, Sette A. A decaepitope polypeptide primes for multiple CD8+ IFN-gamma and Th lymphocyte responses: evaluation of multiepitope polypeptides as a mode for vaccine delivery. J Immunol. 2002;168(12):6189–98. https://doi.org/10.4049/jimmunol.168.12.6189.
Duperret EK, Perales-Puchalt A, Stoltz R, G HH, Mandloi N, Barlow J, et al. A synthetic DNA, multi-neoantigen vaccine drives predominately MHC class I CD8(+) T-cell responses, impacting tumor challenge. Cancer Immunol Res 2019;7(2):174–182, doi: https://doi.org/10.1158/2326-6066.CIR-18-0283.
Levy A, Pitcovski J, Frankenburg S, Elias O, Altuvia Y, Margalit H, Peretz T, Golenser J, Lotem M. A melanoma multiepitope polypeptide induces specific CD8+ T-cell response. Cell Immunol. 2007;250(1–2):24–30. https://doi.org/10.1016/j.cellimm.2008.01.001.
Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, Offringa R, van der Burg SH. CD8+ CTL priming by exact peptide epitopes in incomplete Freund’s adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol. 2007;179(8):5033–40. https://doi.org/10.4049/jimmunol.179.8.5033.
Kreiter S, Castle JC, Tureci O, Sahin U. Targeting the tumor mutanome for personalized vaccination therapy. Oncoimmunology. 2012;1(5):768–9. https://doi.org/10.4161/onci.19727.
Neisig A, Roelse J, Sijts AJ, Ossendorp F, Feltkamp MC, Kast WM, et al. Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I-presentable peptides and the effect of flanking sequences. J Immunol. 1995;154(3):1273–9.
Kiwala S, Graubert A, mrjosh, Wollam A, Griffith M, amberzw, et al. griffithlab/pVACtools: 2.0.0 (version v2.0.0). Github. doi: https://doi.org/10.5281/zenodo.4520122. 2021.
Johnson ES, Bartel B, Seufert W, Varshavsky A. Ubiquitin as a degradation signal. EMBO J. 1992;11(2):497–505. https://doi.org/10.1002/j.1460-2075.1992.tb05080.x.
Johnson ES, Ma PC, Ota IM, Varshavsky A. A proteolytic pathway that recognizes ubiquitin as a degradation signal. J Biol Chem. 1995;270(29):17442–56. https://doi.org/10.1074/jbc.270.29.17442.
Kim PK, Hailey DW, Mullen RT, Lippincott-Schwartz J. Ubiquitin signals autophagic degradation of cytosolic proteins and peroxisomes. Proc Natl Acad Sci U S A. 2008;105(52):20567–74. https://doi.org/10.1073/pnas.0810611105.
Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–5. https://doi.org/10.1126/science.aar4060.
Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–61. https://doi.org/10.1016/j.ccell.2015.03.001.
Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–86. https://doi.org/10.1158/2159-8290.CD-18-0367.
Li L, Zhang X, Wang X, Kim SW, Herndon JM, Becker-Hapak M, et al. Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation. BioProject PRJNA685845. Sequence Read Archive (SRA). https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA685845. 2020. Accessed 12 Mar 2021.
Li L, Zhang X, Wang X, Kim SW, Herndon JM, Becker-Hapak M, et al. Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation. Study Accession phs002342.v1.p1. The database of Genotypes and Phenotypes (dbGaP). http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002342.v1.p1. 2021. Accessed 14 Mar 2021.
We thank the McDonnell Genome Institute at Washington University School of Medicine in St Louis for genome sequencing and analysis services. We would also like to thank Enid McIntosh for administrative assistance.
This project was supported by grants from Susan G. Komen for the Cure (KG111025), the Alvin J. Siteman Cancer Center (Siteman Investment Program grant 4035), the National Institute of Health (NIH) grant R01 CA240983, the National Cancer Institute (NCI) at NIH (Cancer Center Support Grant P30-CA091842, and SPORE in Pancreatic Cancer P50-CA196510), NCI training grant T32 CA009621, and the Foundation for Barnes-Jewish Hospital (to SPG).
Ethics approval and consent to participate
Animal protocols were approved by the Animal Studies Committee of Washington University School of Medicine and were in accord with IACUC guidelines and procedures. The neoantigen DNA vaccine treatment protocol was approved by the Institutional Research Board at Washington University School of Medicine. The patient signed written informed consent documents for the treatment and associated research studies. The research conformed to the principles of the Helsinki Declaration.
Consent for publication
The research protocol and informed consent document allows sharing and publication of the patient’s clinical details and deidentified data, including sharing of raw sequencing data in public repositories such as dbGaP.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Additional file 1.
This file contains the DNA and amino acid sequences of the polyepitope DNA vaccines created for this study.
Additional file 2:
This file contains Supplementary Table S1 to S4. Table S1. List of HLA-A2-restricted epitopes included in the octamers for optimizing polyepitope DNA vaccine design; Table S2. Selective neoantigens identified in E0771 mouse breast cancer; Table S3. Neoantigens identified in mouse breast cancer cell line 4T1.2; and Table S4. Neoantigens identified in cancer patient GTB16.
Additional file 3:
This file contains Supplementary Methods and Supplementary Figure S1 to S4. Figure S1. Expression of polyepitope constructs and the presentation of antigens. Figure S2. SLP vaccines generated neoepitope-specific CD4 T cell responses. Figure S3. Ubmut-4T1.2 Polyepitope neoantigen DNA vaccine inhibits 4T1.2 tumor growth in vivo. Figure S4. Both MT and WT Lrrc27 peptides bind well to H-2Db.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Li, L., Zhang, X., Wang, X. et al. Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation. Genome Med 13, 56 (2021). https://doi.org/10.1186/s13073-021-00872-4
- Polyepitope DNA vaccine
- Breast cancer